EGFR-tyrosine kinase inhibitors (TKIs) offer better efficacy and quality of life for lung cancer patients [8, 9], and have hence emerged as an important frontline therapy for patients with EGFR-mutant, non-small cell lung cancer [10]. Here, EGFR is linked to lung carcinoma.